PMID- 12463462
OWN - NLM
STAT- MEDLINE
DCOM- 20030513
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 20
IP  - 6 Suppl 28
DP  - 2002 Nov-Dec
TI  - Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated 
      spondyloarthropathy.
PG  - S126-9
AB  - The cytokine tumour necrosis factor (TNF)-alpha plays a major role in the spinal 
      inflammatory process of spondyloarthropathy. In contrast to rheumatoid arthritis, 
      disease modifying antirheumatic drugs have not been proved effective against 
      inflammation and progressive ankylosis. Initial studies on TNFalpha inhibitors in 
      ankylosing spondylitis are promising and raise the question as to whether early 
      stages of the disease, mostly classified as "undifferentiated 
      spondyloarthropathy" (uSpA), should also be treated with TNFalpha inhibitors. 
      This article summarises the preliminary results of 11 uSpA patients in 4 
      different trials treated with TNFalpha inhibitors.
FAU - Schnarr, S
AU  - Schnarr S
AD  - Hannover Medical School, Department of Internal Medicine, University of Hannover, 
      Germany. schnarr.sebastian@mh-hannover.de
FAU - Kuipers, J G
AU  - Kuipers JG
FAU - Zeidler, H
AU  - Zeidler H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Etanercept
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Infliximab
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Spondylarthropathies/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
RF  - 21
EDAT- 2002/12/05 04:00
MHDA- 2003/05/14 05:00
CRDT- 2002/12/05 04:00
PHST- 2002/12/05 04:00 [pubmed]
PHST- 2003/05/14 05:00 [medline]
PHST- 2002/12/05 04:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S126-9.